CKD 519

Drug Profile

CKD 519

Alternative Names: CKD-519

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator Chong Kun Dang
  • Class Antihyperlipidaemics
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dyslipidaemias

Most Recent Events

  • 29 Nov 2016 Chong Kun Dang Pharmaceutical plans a phase II trial for Dyslipidaemias (Combination therapy) in Australia (PO) (NCT02977065)
  • 01 Aug 2016 Chong Kun Dang initiates a phase I trial in Healthy volunteers in South Korea (PO, Tablet) (NCT02916901)
  • 01 Aug 2016 Phase-I clinical trials in Dyslipidaemias (In volunteers) in South Korea (PO, Capsule) (NCT02894541)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top